📊 TVTX Key Takeaways
Is Travere Therapeutics, Inc. (TVTX) a Good Investment?
Travere demonstrates exceptional 110.5% revenue growth with dramatically improving losses (92.1% YoY), achieving positive free cash flow of $37.4M despite negative net income. Strong balance sheet with low debt (0.20x D/E), solid liquidity (2.74x current ratio), and $93M cash position provide financial stability for a pharmaceutical growth-stage turnaround approaching profitability.
Why Buy Travere Therapeutics, Inc. Stock? TVTX Key Strengths
- Exceptional revenue growth of 110.5% YoY indicates successful product commercialization and market acceptance
- Positive free cash flow of $37.4M (7.6% FCF margin) despite net losses demonstrates underlying business viability
- Strong financial position with low leverage (0.20x D/E), substantial cash reserves ($93M), and excellent liquidity (2.74x current ratio)
- Significant improvement in net income losses (-92.1% YoY), trending toward profitability
- Conservative capital requirements with minimal CapEx ($375K) typical of asset-light pharma model
TVTX Stock Risks: Travere Therapeutics, Inc. Investment Risks
- Still unprofitable with operating margin of -12.8% and net margin of -5.2%, indicating operating expenses not yet scaled with revenue
- Negative interest coverage ratio (-22.4x) reflects inability to cover interest from operating earnings
- Sustainability of 110% growth rate uncertain; typical for pharmaceutical commercialization cycles and subject to regulatory/competitive pressure
- Operating losses and limited profitability runway; with $93M cash and $37.4M annual FCF burn, company has approximately 2.5 years before cash depletion if losses continue at current levels
- Elevated insider trading activity (27 Form 4 filings in 90 days) may indicate significant management changes or uncertainty
Key Metrics to Watch
- Operating margin trajectory and timeline to positive operating income
- Quarterly revenue growth rate stability and product pipeline contribution
- Cash runway and path to sustained profitability based on current burn rate
- Operating expense ratio as percentage of revenue and cost structure optimization
- Free cash flow sustainability and reinvestment in R&D and commercial operations
Travere Therapeutics, Inc. (TVTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
TVTX Profit Margin, ROE & Profitability Analysis
TVTX vs Healthcare Sector: How Travere Therapeutics, Inc. Compares
How Travere Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Travere Therapeutics, Inc. Stock Overvalued? TVTX Valuation Analysis 2026
Based on fundamental analysis, Travere Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Travere Therapeutics, Inc. Balance Sheet: TVTX Debt, Cash & Liquidity
TVTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Travere Therapeutics, Inc.'s revenue has grown significantly by 116% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.50 indicates the company is currently unprofitable.
TVTX Revenue Growth, EPS Growth & YoY Performance
TVTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $62.9M | $25.7M | $0.28 |
| Q2 2025 | $54.1M | -$12.8M | $-0.14 |
| Q1 2025 | $41.4M | -$41.2M | $-0.47 |
| Q3 2024 | $37.1M | -$21.2M | $-0.29 |
| Q2 2024 | $32.2M | -$70.4M | $-0.91 |
| Q1 2024 | $30.9M | -$86.3M | $-1.27 |
| Q3 2023 | $28.1M | -$21.2M | $-0.29 |
| Q2 2023 | $54.2M | -$67.0M | $-1.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Travere Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TVTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Travere Therapeutics, Inc. (CIK: 0001438533)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 16, 2026 | 4 | xslF345X06/form4-04162026_040407.xml | View → |
| Apr 16, 2026 | 4 | xslF345X06/form4-04162026_040405.xml | View → |
| Apr 16, 2026 | 4 | xslF345X06/form4-04162026_040403.xml | View → |
| Apr 15, 2026 | 4 | xslF345X06/form4-04162026_010423.xml | View → |
| Apr 15, 2026 | 4 | xslF345X06/form4-04162026_010440.xml | View → |
❓ Frequently Asked Questions about TVTX
What is the AI rating for TVTX?
Travere Therapeutics, Inc. (TVTX) has an AI rating of BUY with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TVTX's key strengths?
Claude: Exceptional revenue growth of 110.5% YoY indicates successful product commercialization and market acceptance. Positive free cash flow of $37.4M (7.6% FCF margin) despite net losses demonstrates underlying business viability.
What are the risks of investing in TVTX?
Claude: Still unprofitable with operating margin of -12.8% and net margin of -5.2%, indicating operating expenses not yet scaled with revenue. Negative interest coverage ratio (-22.4x) reflects inability to cover interest from operating earnings.
What is TVTX's revenue and growth?
Travere Therapeutics, Inc. reported revenue of $490.7M.
Does TVTX pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
Where can I find TVTX SEC filings?
Official SEC filings for Travere Therapeutics, Inc. (CIK: 0001438533) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TVTX's EPS?
Travere Therapeutics, Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TVTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Travere Therapeutics, Inc. has a BUY rating with 65% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is TVTX stock overvalued or undervalued?
Valuation metrics for TVTX: ROE of -22.2% (sector avg: 15%), net margin of -5.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TVTX stock in 2026?
Our dual AI analysis gives Travere Therapeutics, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TVTX's free cash flow?
Travere Therapeutics, Inc.'s operating cash flow is $37.8M, with capital expenditures of $375.0K. FCF margin is 7.6%.
How does TVTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.2% (avg: 12%), ROE -22.2% (avg: 15%), current ratio 2.74 (avg: 2).